Saturday, 4 August 2018

Pharmaceutical counterfieting

www.pharmaactddossiers.com
Counterfeiting
A counterfeit medicine is one which is deliberately and fraudulently mislabeled with respect to identity and/ or source. 
Counterfeiting of medicines can apply to both branded and generic products. Generally, counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with in correct quantities of activities ingredients or with fake packaging
 Counterfeit Medicines

Products marketed with intent to deceive


1– Counterfeit active/bulk ingredients
2– Counterfeit finished products
3– Unregulated diverted products
4– Counterfeit labeling
5– Mislabeled substances (e.g., generic anti-biotics)

SAMPRGMR ON INSTAGRAM

Why are Medicines a Target?

  1. Fakes can be made relatively cheaply (at least as profitable as narcotics – lower risk).
  2. Many countries, especially in the developing world lack adequate regulation and enforcement
  3. Even in the industrialized countries, the risk of prosecution and penalties for counterfeiting are inadequate
  4. The way in which medicines reach the consumer is also different from other goods:  the end-user has little knowledge of the product – a ‘credence’ good


What is Particular to  Pharmaceutical Counterfeiting?

  1. Medicine counterfeiting is much more of a threat to public health than to company revenues
  2. Developing countries are the worst affected where regulatory structure is weaker and measurement and oversight is difficult; consumers in LDC’s often buy Rx drugs directly over the counter
  3. Non-branded generics are very widely counterfeited (e.g., ampicillin, paracetamol)
  4. Prices vary widely across the world, and parallel trade is widespread, allowing counterfeit medicines to enter the supply chain
  5. People will not knowingly buy a counterfeit drug, but consumer detection is extremely difficult: price is not an indicator in insured markets    
Current and Future Risks
  1. Treatment failure in malaria, TB and HIV/AIDS
  2. Growth of resistance to existing anti-infectives from use of sub-par treatments
  3. Spread of drug resistant pandemics, including HIV and influenza
  4. Use of illegal funds to finance further illegal manufacture of medicines and even terrorism
  5. Globalization of pharmaceutical production know-how drives counterfeiting: supply-driven
  6. Counterfeit drugs are increasingly showing up in OECD countries

Please check out our Website


South Africans need to return 318,000 packets of potentially dangerous pills


The South African distributor of heart pills that may contain a potentially carcinogenic ingredient has confirmed that more than 318,000 packets of pills may be affected.
“Operationally, it is a difficult situation,” a representative of Pharma Dynamics, the distributor of the tablets in South Africa, told Business Insider South Africa.
The South African Health Products Regulatory Authority (SAHPRA) this week recalled Dynaval Co high blood pressure and heart pills, which may contain a controversial carcinogenic ingredient that was manufactured in China.
Dynaval Co 80/12.5 mg, 160/12.5 mg and 160/25 mg pills, which were manufactured by Zhejiang Huahai Pharmaceuticals, may contain the chemical NDMA.
NDMA is associated with liver damage and liver cancer in rats as part of laboratory tests, says dr Eric Decloedt, a clinical pharmacologist at the department of medicine of the University of Stellenbosch. “We extrapolate that it could hold the same risks for people.”
The affected pills contain the ingredient valsartan, but only tablets manufactured by Zhejiang may contain the NDMA. Dynaval 80 mg and 160 mg tablets are not affected.
The Dynaval Co pills were not available in the state health sector, but were in wide use among private patients, who used it for high blood pressure,  heart failure and as part of treatment after a heart attack.
According to Nicole Jennings, corporate communications manager of Pharma Dynamics, more than 318,000 packets of the pills are still in circulation. Anyone with a packet of Dynaval Co should urgently return the medicine to their pharmacy.
European authorities first announced a recall of the batch of medicines that was manufactured by Zhejiang earlier this month. It took a full three weeks for the local authorities to order its withdrawal in South Africa. 
"The responsibility of managing this matter and communicating this information to the public is shared by both SAHPRA and the manufacturers," a SAHPRA spokesperson told Business insider.
“Once SAHPRA was informed by Pharma Dynamics about the affected products, appropriate actions were undertaken in consultation with the manufacturer, to warn healthcare professionals and the public about this potential risk.”
She said that to date, SAHPRA has not identified other valsartan containing products that are affected.
At this stage reports around the impurity possibly causing cancer has not been verified by any health authority, said Jennings.  
“No definitive information has been received to indicate an immediate threat to patients as investigations are still underway."
People who have been using the medicine can get a refund from their pharmacies.
A Pharma Dynamics spokesperson warned that it is dangerous to just stop using the medication – they need to speak to a pharmacist or doctor first about a substitution. The company doesn’t have any immediate plans to foot these doctors’ bills, however.
Decloedt says other medicines containing losartan, candesartan or telmisartan – and pills that contain valsartan but not NDMA – could be prescribed.
please refer to our website for pharma regulatory documentation

Wednesday, 1 August 2018

Regulatory intelligence



Pharma regulatory intelligence


Less complexity. More clarity.

Regulatory intelligence refers to the process of gathering, monitoring and analyzing regulatory information and data to track developments in the changing regulatory environment. Banking, financial services, and insurance sectors continue to experience unprecedented volumes of regulatory change and complexity. Our unique one-stop Regulatory Intelligence provides world-class content and advanced technology that cuts through the complexity and the sheer volume of content and developments within the regulatory compliance environment. That’s how we can provide clarity on what is most important to your organization – in a cost effective way.


Unsurpassed breadth, depth and quality

Regulatory Intelligence includes global coverage of over 900 regulatory bodies and more than 2,500 collections of regulatory and legislative materials. It is powered by exclusive news, analysis, and practical guidance from our global team of regulatory compliance experts and journalists, and it has an intuitive user interface with powerful search functionality and easy navigation. This way, you can access whatever information you need, when you need it, from one single source.

Regulatory Intelligence Feeds incorporates our client-driven taxonomy to automate the flow of regulatory information into your organization. Content is extracted from our regulatory database – the same source that drives our Regulatory Intelligence solution. This allows for a smarter and easier workflow to be created in the application, and by utilizing our data feed in your compliance activities, you can be assured that the business is reviewing and implementing regulatory change as it occurs.


Features
Single information source
A cost-effective and simplified research process, with comprehensive content, intuitive features ,and user-friendly functionality. Focus on anticipating and navigating the regulatory environment, alongside your general day-to-day responsibilities, by taking away the burden of having to manually track and monitor multiple and varied sources of regulatory information.
More focus, less noise
Focus on the information needed to quickly reach informed and targeted decisions. Keep track of regulatory developments that specifically impact your organization through powerful features to search, filter, and automatically monitor the relevant developments.
Trusted and reliable
Our trusted global regulatory experts and editorial team, who analyze news and events on a daily basis, provide analysis and practical guidance. They provide hot topics and news and impact analysis of current and forthcoming regulations. The breadth and depth of the knowledge and expertise that goes into the collection and analysis of regulatory developments means that you consistently have access to the most thorough, accurate, and reliable regulatory information available.
Manage regulatory risk
With the shift towards bigger fines and greater personal liability, the need for organizations and compliance professionals to stay compliant has never been greater. Regulatory Intelligence reduces the potential room for errors and vulnerability within your organization by providing information that has been stringently tracked, monitored, and analyzed. Content is structured and maintained to ensure you have the most up-to-date information at all times to manage and mitigate risk.
Practical and actionable information
Thomson Reuters Regulatory Intelligence gives constant access to practical advice, best practice materials, and knowledge to implement relevant regulatory changes within your organization, and to make sure organizational structures are aligned to current and upcoming regulations. Information and reports can be created and customized for valuable and meaningful board level reporting and shared within the organization.
Concise information for a focused view
Content within Regulatory Intelligence has been configured to ensure you can easily find the relevant information to get clarity on what is most important to your organization. This simplifies the research process, as you do not have to spend time sifting through vast amounts of irrelevant information.
for more information please check our Website

HAPPY-NEW-YEAR